Xenetic Biosciences, Inc. (XBIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenetic Biosciences, Inc. on April 20, 2020. The Company is a biopharmaceutical entity incorporated in Nevada with principal executive offices in Framingham, Massachusetts. Its common stock and purchase warrants trade on The NASDAQ Stock Market LLC under the symbols "XBIO" and "XBIOW," respectively.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock listing standards rather than financial performance.
Material Changes and Events
On April 20, 2020, the Company received a written notice from the Listing Qualifications Department of the NASDAQ Stock Market LLC. The notice stated that the closing bid price for the Company's common stock had been below $1.00 for 30 consecutive business days, resulting in non-compliance with Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Requirement").
- Immediate Effect: The notice has no immediate effect on the listing of the Company's common stock.
- Compliance Timeline: Due to market conditions, Nasdaq tolled the compliance period through June 30, 2020. The reinstatement date is July 1, 2020.
- Deadline: The Company has 180 calendar days from the reinstatement date, until December 28, 2020, to regain compliance.
- Requirement: To regain compliance, the closing bid price must be at least $1.00 for a minimum of ten consecutive business days prior to the Compliance Date.
Outlook, Risks, and Management Commentary
Management intends to monitor the closing bid price and may consider available options to regain compliance, including a reverse stock split if necessary. However, the Company explicitly states there can be no assurance that it will be able to regain compliance with the Bid Price Requirement or other Nasdaq Listing Rules.
If the Company fails to regain compliance by the Compliance Date, it may be eligible for an additional 180-day compliance period. Qualification for this second period requires meeting the market value of publicly held shares requirement and all other initial listing standards, excluding the Bid Price Requirement.
Investor Verification Checklist
- Verify the current closing bid price of XBIO common stock to assess proximity to the $1.00 threshold.
- Monitor the Company's stock price performance between July 1, 2020, and December 28, 2020, to determine if the 10-day compliance window is met.
- Review subsequent filings for announcements regarding a potential reverse stock split.
- Check for any further communications from Nasdaq regarding the Company's listing status or potential delisting.